Has Quizartinib been officially launched in China?

Quizartinib has received widespread attention worldwide. It is mainly used to treat patients with relapsed or refractory acute myeloid leukemia (AML), especially the FLT3-ITD positive subtype. This type of leukemia usually progresses rapidly, has a high relapse rate, and has limited response to traditional chemotherapy, and is in urgent need of targeted drug intervention. Quizartinib selectively inhibits FLT3 receptor tyrosine kinase activity and blocks downstream signaling, thereby effectively inhibiting leukemia cell proliferation and inducing apoptosis, and has shown significant anti-leukemia potential in clinical studies.

However, so far, the original drug Quizartinib has not been officially launched in China, so there are still uncertainties in domestic price and medical insurance coverage. Although some companies in the domestic market are carrying out clinical research and registration applications, they have not yet obtained marketing approval from the National Food and Drug Administration (NMPA). This means that if Chinese patients need to use quizartinib, they can only obtain it through clinical trials or overseas purchases, and there are great limitations on the actual cost and accessibility of the drug. In overseas markets, the price of quizartinib is usually higher, but its targeted efficacy in high-risk AML patients provides value support for its high cost.

In China,AML is still one of the more difficult diseases to treat among hematological malignancies, and FLT3-ITD-positive patients are more likely to experience treatment failure or relapse. The introduction of quizartinib indicates that targeted therapy will provide new treatment options for these high-risk patients. Drug R&D companies are also actively promoting clinical trials in China to obtain more safety and efficacy data on Chinese patients to provide basis for final marketing. Once approved, quizartinib will fill the gap in targeted therapy for FLT3-ITD-positive AML patients in China and is expected to become an important part of the treatment of high-risk leukemia.

Reference materials:https://go.drugbank.com/drugs/DB12874